The U.S. Food and Drug Administration has approved a new two-drug combination that significantly reduces the chance of kidney cancer returning after surgery. The treatment pairs pembrolizumab, an immunotherapy, with belzutifan, a targeted therapy, for adults with clear cell renal cell carcinoma who face an intermediate-high or high risk of recurrence. The decision offers a powerful new option for patients who have had their tumor removed but still face a substantial threat of the cancer coming back.
The approval stems from the phase 3 LITESPARK-022 trial, which included 1,841 participants. All had undergone nephrectomy to remove their kidney tumor and showed no signs of active cancer, yet carried an elevated risk of relapse. Patients were randomly assigned to receive either pembrolizumab plus belzutifan after surgery or pembrolizumab plus a placebo. After a median follow-up of about 28 months, the combination lowered the risk of recurrence, metastasis or death by 28 percent. At the two-year mark, 81 percent of patients on the dual therapy remained cancer-free, compared to 74 percent of those who received pembrolizumab alone.
Belzutifan works by blocking a protein called HIF-2 alpha, which is overabundant in clear cell renal cell carcinoma cells and drives tumor growth. The science behind this approach earned Dana-Farber Cancer Institute researcher Dr. William G. Kaelin Jr. a Nobel Prize in 2019. This marks the first approval of belzutifan for earlier-stage kidney cancer and the first approval of a combination regimen pairing a PD-1 inhibitor with a HIF-2 alpha inhibitor. Side effects observed in the trial were consistent with those reported in previous studies of the individual drugs.
For patients with clear cell renal cell carcinoma, which accounts for about 75 percent of kidney cancer diagnoses, the news is significant. Roughly 30 percent of these patients experience disease recurrence within five years after surgery alone. With this new adjuvant option, doctors now have a more effective strategy to help prevent relapse and improve long-term outcomes. Researchers continue to monitor trial participants to assess long-term survival benefits, and the approval opens the door for broader use of belzutifan in earlier stages of the disease.